Details

Autor(en) / Beteiligte

• Wu, Sherry Y
• Rupaimoole, Rajesha
• Shen, Fangrong
• Pradeep, Sunila
• Pecot, Chad V
• Ivan, Cristina
• Nagaraja, Archana S
• Gharpure, Kshipra M
• Pham, Elizabeth
• Hatakeyama, Hiroto
• McGuire, Michael H
• Haemmerle, Monika
• Vidal-Anaya, Viviana
• Olsen, Courtney
• Rodriguez-Aguayo, Cristian
• Filant, Justyna
• Ehsanipour, Ehsan A
• Herbrich, Shelley M
• Maiti, Sourindra N
• Huang, Li
• Kim, Ji Hoon
• Zhang, Xinna
• Han, Hee-Dong
• Armaiz-Pena, Guillermo N
• Seviour, Elena G
• Tucker, Sue
• Zhang, Min
• Yang, Da
• Cooper, Laurence J N
• Ali-Fehmi, Rouba
• Bar-Eli, Menashe
• Lee, Ju-Seog
• Ram, Prahlad T
• Baggerly, Keith A
• Lopez-Berestein, Gabriel
• Hung, Mien-Chie
• Sood, Anil K

Titel

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer

Ist Teil von

• Nature communications, 2016-04, Vol.7 (1), p.11169-14, Article 11169

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2016

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• A deeper mechanistic understanding of tumour angiogenesis regulation is needed to improve current anti-angiogenic therapies. Here we present evidence from systems-based miRNA analyses of large-scale patient data sets along with in vitro and in vivo experiments that miR-192 is a key regulator of angiogenesis. The potent anti-angiogenic effect of miR-192 stems from its ability to globally downregulate angiogenic pathways in cancer cells through regulation of EGR1 and HOXB9. Low miR-192 expression in human tumours is predictive of poor clinical outcome in several cancer types. Using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes, we show that miR-192 delivery leads to inhibition of tumour angiogenesis in multiple ovarian and renal tumour models, resulting in tumour regression and growth inhibition. This anti-angiogenic and anti-tumour effect is more robust than that observed with an anti-VEGF antibody. Collectively, these data identify miR-192 as a central node in tumour angiogenesis and support the use of miR-192 in an anti-angiogenesis therapy.